不同剂量生大黄粉在危重病患者肠胃并发症的临床研究

目的：分析和研究不同剂量生大黄粉在危重病患者肠胃并发症的临床治疗效果。方法选取我院2011年3月-2013年8月内科收治的危重患者58例，将其按双盲随机方法分为两组，观察组29例与对照组29例。两组患者均给予对症治疗，对照组患者在对症治疗基础上按每千克体重计算加用大黄粉0.05 g/次；观察组患者在对症治疗基础上按每千克体重计算加用大黄粉1.5 g/次，治疗5天后，将两组患者治疗效果进行对比。结果观察组患者胃肠功能衰竭率、上消化道出血发生率明显低于对照组（P ﹤0.05），具有统计学意义。观察组患者肠内营养供给时间、住院天数、每日大便次数等项指标均低于对照组（P ﹤0.05），具有统计学意义。观察组患者炎症指标、肾功能指标检测值均优于对照组（P ﹤0.05），具有统计学意义。结论将大剂量生大黄粉应用于危重病患者肠胃并发症治疗中，能够有效改善患者肾功能，控制炎症反应，减少胃肠功能衰竭及上消化道出血等情况发生，对提高救治成功率有重要意义。

Clinical studies of different doses of rhubarb powder on gastrointestinal complications in critically ill patients

Objective：To analyze and study the clinical efficacy of different doses of rhubarb powder on gastrointestinal complications in critically ill patients. Methods：Fifty-eight cases with critical illness in our hospital from March 2011 to August 2013 were respectively analyzed. Patients were randomly divided into two groups,with 29 cases in each. The pa-tients of the control group were treated with symptomatic treatment and rhubarb（0. 05g/ times,per kilogram of body weight）. The patients of the observation group were treated with symptomatic treatment and rhubarb（1. 5 g/ times,per kilo-gram of body weight）. After 5 days＆#39;treatment,the efficacy of two groups was compared. Results：The gastrointestinal dys-function rate and upper gastrointestinal bleeding incidence of the observation group were significantly lower than those of the control group（P ﹤ 0. 05）. The supply time,hospital stay,and daily stool frequency indexes of the observation group were significantly lower than those of the control group（P ﹤ 0. 05）. The inflammatory markers and renal function value of the observation group were significantly higher than those of the control group（P ﹤ 0. 05）. Conclusion：The use of high-dose rhubarb powder to treat the gastrointestinal complications of critically ill patients can effectively improve renal function,con-trol inflammation,reduce the occurrence of gastrointestinal dysfunction and upper gastrointestinal bleeding,and it is impor-tant for improving the success rate in treatment.